Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment

Inclusion Criteria:

• Patients enrolled in LungMate clinical trial series, including:

1. LungMate-001: Clinical study for neoadjuvant anti-PD-1 inhibitor, sintilimab,chemotherapy combined with surgery in treating phase IB - IIIA non-small celllung cancer
2. LungMate-002: Clinical study for neoadjuvant therapy of anti-PD-1 drug combinedwith radical surgery in treating phase IIb - III non-small cell lung cancerpatients
3. LungMate-003: Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy forNon-small Cell Lung Cancer
4. LungMate-004: Neoadjuvant Afatinib Therapy for Potentially Resectable Stage IIIEGFR Mutation-Positive Lung Adenocarcinoma
5. LungMate-005: Clinical Study of PD-L1 Antibody (TQB2450) Plus Chemotherapy (Cisplatin and Etoposide) for Previously Untreated Small Cell Lung Cancer
6. LungMate-006: Clinical Study of PD-1 Antibody (BGB-A317) Plus Chemotherapy (Cisplatin and Etoposide) for Limited Stage Small Cell Lung Cancer
7. LungMate-007: Neoadjuvant HS-10296 (Almonertinib) Therapy for PotentialResectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
8. LungMate-009: Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
9. LungMate-012: Neoadjuvant Furmonertinib Plus Bevacizumab or FurmonertinibMonotherapy for Resectable and Potentially Resectable Stage III-IVA EGFRMutation-Positive Lung Adenocarcinoma
10. LungMate-013: Induction Therapy With PD-1 Antibody Combined With Platinum-basedDoublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer;
11. LungMate-015: The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stageSmall Cell Lung Cancer;
12. Patients enrolled in the LungMate series of neoadjuvant therapy lung cancerclinical trials in the future;

• Age 18- years or older;
• Histopathologically confirmed with NSCLC or SCLC;
• Written Informed consent

Exclusion Criteria:

• The patients who failed to meet clinical trial screening criteria and those whodropped out of the clinical trial;
• Any condition which in the Investigator's opinion makes it undesirable for the subjectto participate in the trial or which would jeopardize compliance with the protocol
• The patient suffered from other cancers besides NSCLC (except cervical carcinoma insitu, cured basal cell carcinoma, and bladder epithelial tumor [including Ta and Tis])within 5 years before the trial;
• The patient is a carrier of active hepatitis B, hepatitis C or HIV.